about
Guidelines for the use and interpretation of assays for monitoring autophagyLithium Modulates Autophagy in Esophageal and Colorectal Cancer Cells and Enhances the Efficacy of Therapeutic Agents In Vitro and In Vivo.LC3B globular structures correlate with survival in esophageal adenocarcinoma.MiR-193b promotes autophagy and non-apoptotic cell death in oesophageal cancer cellsInduction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulationRole of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor.Retinoid receptor signaling and autophagy in acute promyelocytic leukemia.Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia.RNA interference for multiple myeloma therapy: targeting signal transduction pathways.Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.Glycolysis inhibition as a cancer treatment and its role in an anti-tumour immune response.UBE2L6/UBCH8 and ISG15 attenuate autophagy in esophageal cancer cells.Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.Increased acetylation of lysine 317/320 of p53 caused by BCR-ABL protects from cytoplasmic translocation of p53 and mitochondria-dependent apoptosis in response to DNA damage.Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment.Curcumin induces apoptosis-independent death in oesophageal cancer cells.Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E(2)-independent mechanisms.Beta-catenin transcriptional activity is inhibited downstream of nuclear localisation and is not influenced by IGF signalling in oesophageal cancer cells.Local gene therapy of solid tumors with GM-CSF and B7-1 eradicates both treated and distal tumors.Evaluation of cellular uptake and gene transfer efficiency of pegylated poly-L-lysine compacted DNA: implications for cancer gene therapy.Autocrine secretion of osteopontin results in degradation of I kappa B in Bcr-Abl-expressing cells.Bcr-Abl upregulates cytosolic p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway.Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype.Inhibition of PI3-kinase sensitises HL60 human leukaemia cells to both chemotherapeutic drug- and Fas-induced apoptosis by a JNK independent pathway.Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals.Inhibition of caspase activity delays apoptosis in a transfected NS/0 myeloma cell line.Functional aspects of apoptosis in hematopoiesis and consequences of failure.Analysis of a myosin-like protein and the role of calcium in the E. coli cell cycle.Topoisomerase II alpha expression in acute myeloid leukaemia and its relationship to clinical outcome.Pharmacological agents with inherent anti-autophagic activity improve the cytotoxicity of imatinib.Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics.Expression of oncogenic kinase Bcr-Abl impairs mitotic checkpoint and promotes aberrant divisions and resistance to microtubule-targeting agents.Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis.High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion.Alterations of the retinoic acid receptor alpha (RAR alpha) gene in myeloid and lymphoid malignancies.VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.Topoisomerase II expression in normal haemopoietic cells and chronic lymphocytic leukaemia: drug sensitivity or resistance?Curcumin Affects Components of the Chromosomal Passenger Complex and Induces Mitotic Catastrophe in Apoptosis-Resistant Bcr-Abl-Expressing CellsBcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent mechanism and inhibits calcium-dependent apoptotic signaling
P50
Q21996341-6FA15510-0AA1-422E-A898-2BDAD0C55FC4Q35738879-CD3A25FA-2F7B-46EC-BC11-5B6409F24943Q35743276-EFE470B0-323E-4D02-92C5-B2F93F569D01Q35924139-3E1A4151-F9BC-49FF-812C-01DF8FA0B7A7Q37103762-7491ED8A-AF06-492D-AA83-8D650420EEE9Q37164607-AE3574D1-376F-4D0C-8DA0-629FDB1E1D12Q38201532-ED5DFD3F-F26E-445E-BAFB-8F68FA06C2F9Q38248891-84EE500D-3FB5-47A0-927A-B41647293186Q38550480-FA421DF7-66B0-4180-8C6C-F69A00B4CE0FQ38718484-6C54A22B-035B-4C49-A59C-12438F7BDD57Q38884804-9415CFD0-4401-4BD3-B1BB-9990A2AFC8DBQ38967400-4D4BBC3E-0D25-46B1-8ECF-20E7F32FFDA4Q39188679-9E5557A6-C33C-4BAE-BE0A-A1C501469B25Q39331696-ACE09A81-3CF5-46B6-AF01-B0D44C97BE5CQ39623573-351CBD5A-5A13-43BC-AA67-49F03F1E1692Q39790538-1F8409E5-CAC3-4C1C-9596-078CB51FFF86Q40091818-543C5ECC-EBB9-4C7D-91D0-B91B3ED2A503Q40107043-2011B856-BB86-4E06-B15D-A312D09662EDQ40250415-E194BFDA-DA92-4E64-9713-083E8A22362EQ40264444-E1A726F7-87C1-43AC-875D-121334CA39F4Q40455729-09071922-C2DA-4FAF-BDAC-399D98CD0A29Q40631425-75685304-A0FA-4869-8AEF-E9D4B65FEBCBQ40761403-862603C1-DC06-459B-8CEB-8B839ADE05F4Q40787984-DCAFFB68-3820-4507-B26D-1AA4E6D7AAB1Q40887186-783DD181-C675-492E-B526-06852755174FQ40912998-C579CC4A-EA30-4DC5-BD5A-698432E1B73AQ40913568-41441F50-C6BC-44C4-BA51-82F113836D63Q41167474-99DF075A-D19A-47B0-BB17-B31CA441A92FQ41443225-B396C6BC-FF96-4453-9B8F-3E6DE10EE4EDQ41926213-59680734-E342-498A-9381-8374247BA24BQ41933492-67612492-29CC-445E-B7AC-611D76B50989Q43074223-2BACC59B-0668-4115-8A25-490CE9D21F72Q43202238-A70188FF-4879-4F15-B02C-C2CD1AE7C38DQ44117864-EB1DE4CA-5CC2-410C-93E2-74450829DC2FQ52534561-064AC39D-62FE-4E10-8C87-14EFF6F0F916Q53287191-3F981770-6AB1-4619-B7D5-8C8B6157F7BAQ53294014-B7FBC20F-262B-4A3E-AF81-2C916BACD550Q54234057-8475BE4A-A32E-4F24-97C2-AA804227EEFEQ57650078-21E1726C-D175-4803-B91F-33DADBD0D00AQ57650081-9548CFB7-D945-4A86-9B98-D1D8C9DAEFF3
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sharon L McKenna
@ast
Sharon L McKenna
@en
Sharon L McKenna
@es
Sharon L McKenna
@nl
Sharon L McKenna
@sl
type
label
Sharon L McKenna
@ast
Sharon L McKenna
@en
Sharon L McKenna
@es
Sharon L McKenna
@nl
Sharon L McKenna
@sl
prefLabel
Sharon L McKenna
@ast
Sharon L McKenna
@en
Sharon L McKenna
@es
Sharon L McKenna
@nl
Sharon L McKenna
@sl
P106
P21
P31
P496
0000-0002-6764-6274